Early CDAI levels predict long-term response to JAK inhibitors in RA

A multicentre registry study of 843 rheumatoid arthritis patients treated with JAK inhibitors used trajectory modelling to identify four distinct 52-week disease activity patterns, with remission rates ranging from 0% to 47.7% across groups. The study found that absolute CDAI values at weeks 4 and 12 (thresholds of 12.0 and 9.3, respectively) improved prediction of long-term treatment trajectory more than the rate of change in CDAI over time.

Most relevant for: Patients with rheumatoid arthritis being treated with JAK inhibitors, particularly during early treatment monitoring at 4 and 12 weeks.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.